Introduction: Port-site metastasis (PSM) has been a concern with the common use of minimally invasive surgery, especially laparoscopy in urologic oncology. We conducted this study to provide a review of PSMs reported after minimally invasive surgery in managing urologic malignancies, possible contributing factors and preventive measures.
INTRODUCTION
In recent years, questions have been raised about the oncologic safety of laparoscopic and robotic approach. 1 Even though a large number of specialized centers around the world perform laparoscopy for urologic cancer, 2,3 local recurrence and PSM still remain a concern. 4 When PSMs occur, they often do so in the presence of advanced disease, but it is not uncommon for them to occur in isolation. 5, 6 The first known report of a PSM was by Dobronte et al 7 
in 1978. The authors reported implantation of
Since the first successful laparoscopic nephrectomy in 1991, 1 minimally invasive approaches have been increasingly used in tumor resection and lymph node dissection for urologic cancers. This approach has multiple advantages, including decreased length of hospitalization, decreased pain, faster recovery, and improved cosmesis. 2 Laparoscopic surgery has equivalent oncologic outcomes to open procedures; however, PSM is rare, troubling, and often an unexplained occurrence. The first known occurrence of PSM after a urologic procedure was in 1994, when Stolla et al 9 reported a case of subcutaneous metastasis of bladder transitional cell carcinoma (TCC) after laparoscopic pelvic lymph node dissection. Since then, about 50 PSMs have been reported in the setting of urologic surgery.
10
Port-site metastasis is a multifactorial phenomenon with an as-yet undetermined incidence. Etiological factors include natural malignant disease behavior, host immune status, local wound factors, laparoscopy-related factors, such as aerosolization of tumor cells (the use of gas, type of gas, insufflation and desufflation, and pneumoperitoneum) and sufficient technical experience of the surgeons and operating team (adequate laparoscopic equipment, skill, minimal handling of the tumor), surgical manipulation, wound contamination during instrument change, organ morcellation, and specimen removal. 
MATERIALS AND METHODS
An electronic search of MEDLINE, PubMed, Google Scholar, and HighWire Press of the published literature up to 2017 was carried out using the combined key words "port-site metastasis" and "Urology."
Duplicate references, as well as repeated references to the same data sets, were removed. The articles and case reports directly addressing PSM after minimally invasive surgery for urological malignancy were reviewed. Table 1 11-16 shows the case reports found on MEDLINE, PubMed, Google Scholar, and HighWire Press; search of 
RESULTS

WJOLS
DISCUSSION
In urothelial cancers, port-site recurrence has been reported in a total of 13 cases, as reviewed by Micali et al 8 in an international survey of 19 urologic laparoscopic centers performing a total of 18,750 laparoscopic procedures for urologic malignancies. The incidence was 0.12% (13 of 10,912). Majority of port-site recurrences reported in this survey represented TCC. Of these 13 cases, there were 4 metastatic adrenal carcinomas, 4 urothelial carcinomas, 3 nephroureterectomy cases of upper urothelial carcinoma, 1 case of retroperitoneal lymph node resection for testicular cancer, and 1 case of lymph node resection for penile cancer. Port-site metastasis after laparoscopic extirpative surgery for renal-cell carcinoma (RCC) is extremely rare. Micali et al 8 identified no instances of port-site recurrence in 2,604 cases of laparoscopic radical nephrectomy for RCC. Port-site metastasis is a rare complication of laparoscopic intervention in urologic malignancies. Of the more than 50 reported cases of PSM in the urologic oncology literature, only 10 have occurred after surgery for RCC. 13 First case of camera PSM after robot-assisted partial nephrectomy was reported by Song et al. 12 The estimated incidence of PSM for robotic cystectomy is <0.5%. This is higher than the overall PSM rate for urologic cancers (0.09%). 5 The incidence of tumor seeding in general laparoscopic surgery ranges from 0.8 to 21%. For port-site tumor recurrence to occur, several conditions must be present. There must be release of viable cancer cells from the tumor. There must be a mechanism by which these tumor cells are transported to the port site. Lastly, implantation of the tumor cells at the port site and subsequent growth must occur. It has been hypothesized that several factors may aid in this process, namely (1) the biologic aggressiveness of the tumor, (2) local wound factors, (3) host immune responses, and (4) laparoscopic surgical techniques. 13 Biological aggressiveness of the tumor, represented by grade and stage, plays a decisive role in possible tumor seeding determination, explaining why grades II and III TCCs represent the majority of PSMs in urological procedures. 13 Local wound factors help in the implantation and proliferation of tumor cells at the port site. 13 Cancer cells have high proliferation potential within healing skin incisions or intestinal anastomosis. 17 Tumor cells implant more easily and successfully during early wound healing, adhering to fibrin deposited at the site of surgical wound as a part of normal healing. 18 The presence of growth factors at the wound site promotes the survival and propagation of these cancer cells. As suggested by few animal studies, the port-site incision is more conducive than the laparotomy incision for tumor seeding. 19 Aoki et al 20 suggest that repair of the peritoneum at the trocar entry site may reduce the risk of tumor implantation and subsequent recurrence. Immune depression of the peritoneum occurs during laparoscopic insufflation as demonstrated by macrophage function alteration, resulting in tumor recurrence and metastasis. [21] [22] [23] [24] [25] Overall, immune function is diminished in the perioperative period because of factors like anesthetic agents, opioids, surgical trauma, blood transfusions, temperature changes, pain, and psychological stress. 23 Some studies showed a better preservation of cell-mediated immunity after laparoscopic surgery. 34 However, these benefits are not applied to the peritoneal level, possibly related to the hypoxic environment due to pneumoperitoneum pressure and secondary effect of the carbon dioxide in the peritoneal macrophage response. 34 Factors related to laparoscopic surgical technique contribute to port-site recurrence. 26 These include the use of pneumoperitoneum, trocar site contamination, organ and tumor morcellation, and the method of specimen retrieval. The direct dissemination of tumor cells from contaminated material or from extraction with an open bag has been reported. 5, 6, 23 tissue trauma at trocar sites, combined with leakage of CO 2 , leads to enhanced tumor growth at these sites. In addition to the potential effects of pneumoperitoneum on the transfer of tumor cells, it has also been proposed that malignant cells may be transferred from the tumor to the port site by the aggressive manipulation of the tumor with laparoscopic instruments and the subsequent withdrawal and reinsertion of these contaminated instruments. Hewett et al 27 were the first to demonstrate this concept in a pig model. The importance of minimizing tumor manipulation is first detailed by Greco et al. 16 Irrigating port sites with povidone iodine may lower the risk of port-site recurrence. 29 Local application of cytotoxic agents, such as methotrexate and cyclophosphamide, is also found to be effective. 30 Javali 14 suggested that positron emission tomography and computed tomography could be a useful adjunct in diagnosing port-site recurrence especially in cases presenting within a short span of time following laparoscopic surgery for urological malignancy, wherein induration due to surgical factors at scar site may be confused with port-site recurrence.
Measures suggested in the Literature to prevent Urologic Port-site Metastasis 31 • Avoidance of laparoscopic surgery if ascites is present 9, 31 • Avoidance of gas leakage along the trocar 31 • Avoidance of tumor-boundary violation
• Use of an impermeable bag if morcellation is done 15 • Use of a bag for intact specimen removal • Placement of drain if needed before abdominal deflation 32 • Povidone-iodine irrigation of the laparoscopic instruments, trocar, and port-site wounds. 29 Local application of cytotoxic agents, such as methotrexate and cyclophosphamide, is also found to be effective 30 • Suturing all port sites ≥10 mm 9, 31 Burns et al 33 demonstrated on an animal model that port-site tumor implantation was significantly increased when only skin was closed compared with closure of all three layers. The authors proved that closure technique may influence the rate of port-site tumor implantation.
CONCLUSION
Port-site metastasis in urological laparoscopic surgery is rare and is preventable. Risk can be minimized by applying open surgery oncological procedural principles. 31, 
